Introduction: Iron deficiency anaemia (IDA) is a global health problem. It is common in poverty areas and indicates poor nutrition and health. According to Islamic beliefs, dates and goat milk are considered as superfood for preservation of health. Therefore, this study aimed to determine the beneficial effects of dates and goat milk on IDA. Materials & Methods: A cross-sectional study was conducted among 57 female adults with IDA. They were assigned to 5 groups with different feeding protocol (normal diet, dates, goat milk, both dates and goat milk and ferrous fumarate). Full blood count and iron profile were assessed at the beginning of the study and repeated at weeks 4, 8 and 12. Results: There was significant improvement in reticulocyte count and haemoglobin level in all three groups supplemented with dates and goat milk. The group supplemented with dates also showed increased in packed cell volume (p<0.005) while group supplemented with goat milk showed raised red cell count (p<0.005). The iron profile (ferritin and transferrin level) improved in all three groups supplemented with dates and goat milk (p<0.005). Discussion: Dates and goat milk improved the haematopoietic and iron profile in IDA subjects in accordance with previous reports on animal model. This may be contributed by the high iron content in dates and presence of biochemical components in dates and goat milk that enhanced iron bioavailability. Therefore, inclusion of dates and goat milk may be considered as a supplementary diet in IDA subjects.

Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of large cell lymphoma, characterized by the growth of neoplastic cells within the lumina of small blood vessels, without an obvious extravascular tumor mass or presence of circulating lymphoma cells in the peripheral blood.

Clinical manifestations of sickle cell disease (SCD) arise from the tendency of the sickle haemoglobin to polymerize and deform red blood cells into the characteristic sickle shape. Sickle cell crisis is a devastating complication that may occur in patients with SCD. If not managed properly permanent organ damage and even death may be the final outcome. A case of a 32-year-old Nigerian lady, Gravida 1 Para 0 in her first trimester, with SCD who developed signs and symptoms of delayed haemolytic transfusion reaction after receiving packed red cell transfusion is demonstrated. Multiple red cell alloantibodies were detected in the patient’s plasma; anti-Fy a, anti-Jk b and anti-E. The patient miscarriaged and succumbed to complications of hyperhaemolysis with delayed haemolytic transfusion reaction, acute chest syndrome and renal failure. There is an urgent need for mandatory red cell antibody screen and identification especially in high-risk cases. Prevention of alloimmunization by supplying phenotype-specific red cells is also required.

Clinical manifestations of sickle cell disease (SCD) arise from the tendency of the sickle haemoglobin to polymerize and deform red blood cells into the characteristic sickle shape. Sickle cell crisis is a devastating complication that may occur in patients with SCD. If not managed properly permanent organ damage and even death may be the final outcome. A case of a 32-year-old Nigerian lady, Gravida 1 Para 0 in her first trimester, with SCD who developed signs and symptoms of delayed haemolytic transfusion reaction after receiving packed red cell transfusion is demonstrated. Multiple red cell alloantibodies were detected in the patient's plasma; anti-Fy a, anti-Jk b and anti-E. The patient miscarriaged and succumbed to complications of hyperhaemolysis with delayed haemolytic transfusion reaction, acute chest syndrome and renal failure. There is an urgent need for mandatory red cell antibody screen and identification especially in high-risk cases. Prevention of alloimmunization by supplying phenotype-specific red cells is also required.

BACKGROUND: Antiphospholipid syndrome (APS) is a multisystem disease that may present as venous or arterial thrombosis and/or pregnancy complications with the presence of antiphospholipid antibodies. Until today, heterogeneity of pathogenic mechanism fits well with various clinical manifestations. Moreover, previous studies have indicated that genes are differentially expressed between normal and in the disease state. Hence, this study systematically searched the literature on human gene expression that was differentially expressed in Obstetric APS.METHODOLOGY: Electronic search was performed until 31st March 2015 through PubMed and Embase databases; where the following Medical Subject Heading (MeSH) terms were used and they had been specified as the primary focus of the articles; gene, antiphospholipid, obstetric, and pregnancy in the title or abstract. From 502 studies retrieved from the search, only original publications that had performed gene expression analyses of human placental tissue that reported on differentially expressed gene in pregnancies with Obstetric APS were included. Two reviewers independently scrutinized the titles and the abstracts before examining the eligibility of studies that met the inclusion criteria. For each study; diagnostic criteria for APS, method for analysis, and the gene signature were extracted independently by two reviewers. The genes listed were further analysed with the DAVID and the KEGG pathways.RESULTS: Three eligible gene expression studies involving obstetric APS, comprising the datasets on gene expression, were identified. All three studies showed a reduction in transcript expression on PRL, STAT5, TF, DAF, ABCA1, and HBEGF in Obstetric APS. The high enrichment score for functionality in DAVID had been positive regulation of cell proliferation. Meanwhile, pertaining to the KEGG pathway, two pathways were associated with some of the listed genes, which were ErBb signalling pathway and JAK-STAT signalling pathway.CONCLUSION: Ultimately, studies on a genetic level have the potential to provide new insights into the regulation and to widen the basis for identification of changes in the mechanism of Obstetric APS. Keywords: antiphospholipid, gene, obstetric, pregnancy

Background With the emergence of tyrosine kinase inhibitors and the incorporation of stringent measurable residual disease (MRD) monitoring, risk stratification for BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients has changed significantly. However, whether this monitoring can replace conventional risk factors in determining whether patients need allogeneic stem cell transplantation is still unclear. This study aimed to determine the impact of BCR-ABL1 monitoring on the outcome of patients with BCR-ABL1-positive ALL after allogeneic stem cell transplantation. Methods We retrospectively analyzed the survival outcome of patients with BCR-ABL1-positive ALL based on the quantification of BCR-ABL1 at 3 timepoints: the end of induction (timepoint 1), post-consolidation week 16 (timepoint 2), and the end of treatment for patients who were either transplant-eligible or non-transplant eligible (timepoint 3). Results From 2006 to 2018, a total of 96 patients newly diagnosed with BCR-ABL1-positive ALL were treated with chemotherapy and tyrosine kinase inhibitors. Thirty-eight (41.3%) patients achieved complete remission, and 33 patients underwent allogeneic stem cell transplantation. Our data showed that pre-transplant MRD monitoring by real-time quantitative polymerase chain reaction had the highest correlation with survival in patients with BCR-ABL1-positive ALL, especially for those who underwent allogeneic stem cell transplantation. Conclusion Patients without MRD pre-transplantation had superior survival compared with those who had MRD, and they had excellent long-term outcomes after allogeneic stem cell transplantation.

Cancer-related microangiopathic hemolytic anemia (MAHA) is a rare and life-threatening condition. We present a patient who had been treated for invasive lobular breast carcinoma in clinical remission with fever and hemolytic anemia. The peripheral blood film showed MAHA and thrombocytopenia, and a functional deficiency of ADAMTS13 activity of 23% consistent with acquired thrombotic thrombocytopenic purpura. Bone marrow aspirate and trephine biopsy confirmed metastatic carcinoma. Further evaluation revealed the involvement of multiple bone sites without recurrence of the primary tumor. The patient received a daily plasma exchange with cryosupernatant and was pulsed with corticosteroids. MAHA related to breast cancer appears to be a rare occurrence

The Sysmex XN-3000 is a new automated haematology analyser designed to improve the accuracy of cell counts and the specificity of the flagging events of unusual parameters. By comparing the previous full blood count (FBC) reference intervals in Malaysia for Sysmex XE-5000, we determined a reference interval for all parameters measured by the Sysmex XN-3000 for the Malaysian population. Through the voluntary recruitment of 397 adults ages 18-45 years, both genders, and the three main ethnic groups, FBC was performed on the two analysers. Qualified healthy participants were screened using a health questionnaire. This was followed by reference intervals, probability distribution measurements, and dispersion with point estimate determination. Complete data were available in 390 subjects comprising 222 females and 168 males, which were included in the reference interval calculation. Parameters such as haemoglobin, red blood cell count, platelet count including immature platelet fraction (IPF) showed significant differences in Malaysians. XN-3000 showed excellent precision and linearity results. Within- and between-run precisions were met for all parameters tested, except for IPF. For all parameters tested, ≤ 0.5% carry-over was seen. An acceptable correlation with both XN-3000 and XE-5000 was achieved in comparison studies performed. XN-3000 showed good analytical performance and could provide a solution for laboratories with medium-to-high workloads and evolving clinical needs. Local guidelines are required for the establishment of reference intervals.

Preeclampsia is a pregnancy-specific disorder characterized by the presence of hypertension with the onset of either proteinuria, maternal organ or uteroplacental dysfunction. Preeclampsia is one of the leading causes of maternal and fetal mortality and morbidity worldwide. However, the etiopathologies of preeclampsia are not fully understood. Many studies have indicated that genes are differentially expressed between normal and in the disease state. Hence, this study systematically searched the literature on human gene expression that was differentially expressed in preeclampsia. An electronic search was performed through 2019 through PubMed, Scopus, Ovid-Medline, and Gene Expression Omnibus where the following MeSH (Medical Subject Heading) terms were used and they had been specified as the primary focus of the articles: Gene, placenta, preeclampsia, and pregnancy in the title or abstract. We also found additional MeSH terms through Cochrane Library: Transcript, sequencing, and profiling. From 687 studies retrieved from the search, only original publications that had performed high throughput sequencing of human placental tissues that reported on differentially expressed genes in pregnancies with preeclampsia were included. Two reviewers independently scrutinized the titles and abstracts before examining the eligibility of studies that met the inclusion criteria. For each study, study design, sample size, sampling type, and method for gene analysis and gene were identified. The genes listed were further analyzed with the DAVID, STRING and Cytoscape MCODE. Three original research articles involving preeclampsia comprising the datasets in gene expression were included. By combining three studies together, 250 differentially expressed genes were produced at a significance setting of p < 0.05. We identified candidate genes: LEP, NRIP1, SASH1, and ZADHHC8P1. Through GO analysis, we found extracellular matrix organization as the highly significant enriched ontology in a group of upregulated genes and immune process in downregulated genes. Studies on a genetic level have the potential to provide new insights into the regulation and to widen the basis for identification of changes in the mechanism of preeclampsia. Integrated bioinformatics could identify differentially expressed genes which could be candidate genes and potential pathways in preeclampsia that may improve our understanding of the cause and underlying molecular mechanisms that could be used as potential biomarkers for risk stratification and treatment. � 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Preeclampsia is a pregnancy-specific disorder characterized by the presence of hypertension with the onset of either proteinuria, maternal organ or uteroplacental dysfunction. Preeclampsia is one of the leading causes of maternal and fetal mortality and morbidity worldwide. However, the etiopathologies of preeclampsia are not fully understood. Many studies have indicated that genes are differentially expressed between normal and in the disease state. Hence, this study systematically searched the literature on human gene expression that was differentially expressed in preeclampsia. An electronic search was performed through 2019 through PubMed, Scopus, Ovid-Medline, and Gene Expression Omnibus where the following MeSH (Medical Subject Heading) terms were used and they had been specified as the primary focus of the articles: Gene, placenta, preeclampsia, and pregnancy in the title or abstract. We also found additional MeSH terms through Cochrane Library: Transcript, sequencing, and profiling. From 687 studies retrieved from the search, only original publications that had performed high throughput sequencing of human placental tissues that reported on differentially expressed genes in pregnancies with preeclampsia were included. Two reviewers independently scrutinized the titles and abstracts before examining the eligibility of studies that met the inclusion criteria. For each study, study design, sample size, sampling type, and method for gene analysis and gene were identified. The genes listed were further analyzed with the DAVID, STRING and Cytoscape MCODE. Three original research articles involving preeclampsia comprising the datasets in gene expression were included. By combining three studies together, 250 differentially expressed genes were produced at a significance setting of p < 0.05. We identified candidate genes: LEP, NRIP1, SASH1, and ZADHHC8P1. Through GO analysis, we found extracellular matrix organization as the highly significant enriched ontology in a group of upregulated genes and immune process in downregulated genes. Studies on a genetic level have the potential to provide new insights into the regulation and to widen the basis for identification of changes in the mechanism of preeclampsia. Integrated bioinformatics could identify differentially expressed genes which could be candidate genes and potential pathways in preeclampsia that may improve our understanding of the cause and underlying molecular mechanisms that could be used as potential biomarkers for risk stratification and treatment.

Background: Iron deficiency anaemia is one of the most prevalent nutritional deficiencies in the world which indicates poor nutrition and health. It is characterized by the reduction or absence of serum iron as well as iron stores in the body. Supplementation of calcium rich diet such as animals’ milk is known to have inhibitory effect on iron bioavailability. However, recent studies have found that goat’s milk does not only increase iron bioavailability in iron deficiency anaemia but also minimized the interference of iron absorption. This systematic review aims to evaluate the potential of goat’s milk as a treatment for iron deficiency anaemia. Methods: The search was conducted for relevant articles published in four electronic indexed databases namely Medline, Ovid, Scopus, and PubMed. Relevant reviews, manuscripts and bibliographies of screened studies were searched using Google search engine. Data reporting involved systematic reviews and report of the study according to PRISMA guidelines. Results: A total of eight articles were found to meet the inclusion criteria. It was reported that iron deficient rats treated with goat’s milk showed increased hemoglobin regeneration efficiencies. This was evidenced by increased serum haemoglobin, red blood cell count, packed cell volume, haematocrit and mean cell volume. The DMT-1 receptor in the small intestine was also up-regulated indicating induction of erythropoiesis. These findings were more significant with whole goat’s milk than skim powdered goat’s milk. In iron deficient subjects treated with iron therapy, iron bioavailability was not affected with goat’s milk supplementation whereas it was significantly low with cow’s milk. The serum iron, ferritin, hepcidin levels as well as iron stores in liver, spleen and bone marrow were improved when treated with goat’s milk. In normal rats, iron stores were reduced in the group treated with cow’s milk and high calcium diet but not in the group supplemented with goat’s milk and high calcium diet. Conclusion: This review identified several reports on the beneficial effect of goat milk in iron deficiency anaemia. The findings support the hypothesis that goat’s milk is beneficial in iron deficiency anaemia. The diet of iron deficient subjects is recommended to include goat’s milk as the hemoglobin regeneration efficiencies as well as the iron store are increased. It was also noted that goat’s milk did not interfere with iron absorption and it improves the metabolism and digestion of calcium.